atossatherapeutics.com (ATOS) Company Sales Volume

Atossa Therapeutics, Inc. - graphic logo of issuer ATOS

The biotech sector is currently characterized by a high dependence on capital burn due to a lack of commercial sales. Atossa Therapeutics (ATOS) operating revenue dynamics demonstrate volatility, and the parameter has stabilized at 0.00. The business's defense is based on patents in the field of breast cancer therapy, while Stephen Quay's strategy relies on the successful completion of clinical trials.

Atossa Therapeutics Inc (ATOS): Company Sales from 07/04/2022 to 11/13/2026

Analytical breakdowns for Atossa Therapeutics

- market price and analyst price targets:
Market Price Atossa Pharma|ATOS - Price Target Chart
- market capitalization details:
Market Capitalization Atossa Therapeutics, Inc.|ATOS - Enterprise Value
- issuer book value statistics:
Book Value per Share Atossa Therapeutics|ATOS - Company Net Assets|Market Cap to Book Value Multiple atossatherapeutics.com|ATOS - Aggregate Company Assets
- debt and solvency information:
Debt to Capital Atossa Therapeutics|ATOS - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Atossa Therapeutics Inc|ATOS - Company Debts|Debts to Net Assets Atossa Therapeutics, Inc.|ATOS - Company Long-Term Debts|Company Short-Term Debts Atossa Therapeutics|Intermediate Coverage Ratio atossatherapeutics.com
- net income and valuation ratios data:
ATOS - Net Income|Future Net Profit Atossa Therapeutics|ATOS - P/E Multiple|Future Price to Earnings Multiple atossatherapeutics.com|ATOS - PEG Multiple|Company Value to EBITDA Atossa Therapeutics, Inc.|ATOS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Atossa Therapeutics|ATOS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth atossatherapeutics.com|ATOS - Earnings per share growth in current year|Net earnings per share change forecast for next year Atossa Therapeutics
- issuer revenue and sales details:
ATOS - Revenue and Sales Volume|Company Expected Sales Volume Atossa Pharma|ATOS - Market Cap to Revenue|Forward P/S Multiple Atossa Therapeutics, Inc.
Comprehensive company analysis:Atossa Therapeutics
Original product of Atossa

The business model of Atossa Therapeutics (ATOS) is based on the commercialization of patented cancer drugs. By analyzing the company's operating revenue dynamics, an investor can see the aggregate cash flow from product sales. This metric measures real market demand and the efficiency of intellectual property monetization. For this industry, growth in this indicator confirms the successful navigation of FDA regulatory barriers. The long-term consensus links capitalization to the transition from clinical trials to mass sales.

Key competitors

Company Total Revenue Merus Therapeutics MRUS|Company Revenue Immutep Limited (IMMP)|anixa.com - Company Sales Volume|Revenue and Sales Volume CNTX (Context Therapeutics Inc.)|Revenue and Sales Volume Mersana Therapeutics Inc MRSN|BCTX: Company Sales|ESSA Pharma Inc. - Company Total Sales|QT Imaging Holdings, Inc. (QTI) - Company Revenue